comparemela.com

Latest Breaking News On - Two part - Page 4 : comparemela.com

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis Pharma AG: Novartis data highlight efficacy of Piqray in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.